Table 3 Clinical data of CAR-T cell therapy

Clinical phase

I

I

I/II

II/III

Target

CLL-1/CD33

CLL-1/CD33

Muc1/CLL-1/CD33/CD38/CD56/CD123

CD123/CLL-1

Generation

Second

Second

Fourth

N/A

Costimulatory domain

CD28 for CLL-1/4-1BB for CD33

CD28 for CLL-1/4-1BB for CD33

N/A

N/A

Transduction method

Lentivirus

Lentivirus

N/A

N/A

Patient number

1

1

10

20

Age (years)

44

6

2–75

≦75

Conditioning chemotherapy

FC

FC

N/A

N/A

CAR-T dose

7 × 10⁵/kg

1 × 106/kg/days × 2 days

N/A

N/A

Study start

N/A

N/A

2017

2018

Estimated completion date

N/A

N/A

2020

2021

Status

N/A

N/A

Recruiting

Recruiting

Results

MRD− followed by sibling matched HSCT

complete response, followed by Haplo-HSCT

N/A

N/A

Adverse events

Grade 1 CRS, pancytopenia

Grade 1 CRS, grade 3 neurotoxicity, pancytopenia

N/A

N/A